At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
OTX-TICdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 1 clinical trial evaluating OTX-TIC for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 19 participants across 5 sites.
Detailed Summary
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open Angle Glaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedApr 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartApr 25, 2018
Primary CompletionMay 24, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.2 years ago
Interventions
OTX-TICdrug
OTX-TIC implant is injection in the anterior chamber of the eye